Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05565495

The Effects of ECMO on the Pharmacokinetics of Hydromorphone

Extracorporeal Membrane Oxygenation Clinical Trial

Official title:
The Effects of ECMO on the Pharmacokinetics of Hydromorphone

Clinical Trial Summary

The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.

Clinical Trial Description

A population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO was established. The patients were given hydromorphone 0.03mg/kg/h by continuous intravenous infusion for 72 hours for analgesia. Blood samples were collected at different time points before and after administration, and quantitative liquid chromatography tandem mass spectrometry was used to detect hydromorphone and its main metabolite, hydromorphone-3-glucuronide. ;

Study Design

Related Conditions & MeSH terms

  • Extracorporeal Membrane Oxygenation
Clinical Trial Details
NCT number NCT05565495
Study type Interventional
Source Wuhan Union Hospital, China
Contact You Shang, Prof.
Phone 008602785351607
Email you_shanghust@163.com
Status Recruiting
Phase Phase 2
Start date January 1, 2022
Completion date March 1, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Not yet recruiting NCT05106491 - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients N/A
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Recruiting NCT05444764 - PREdiCtIon of Weanability, Survival and Functional outcomEs After ECLS
Completed NCT05038943 - Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation N/A
Not yet recruiting NCT05341687 - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Recruiting NCT03766282 - Pharmacokinetics in Extracorporeal Membrane Oxygenation
Completed NCT03355625 - Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
Completed NCT01521195 - Oxygen Consumption In Critically Ill Children N/A
Recruiting NCT04620070 - ON-SCENE Initiation of Extracorporeal CardioPulmonary Resuscitation During Refractory Out-of-Hospital Cardiac Arrest N/A
Recruiting NCT06062212 - Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Recruiting NCT05730114 - Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
Completed NCT05154071 - Impact of the Implementation of a Referral Veno-venous Extracorporeal Membrane Oxygenation Centre on Mortality
Recruiting NCT04536272 - Reduced Anticoagulation Targets in ECLS (RATE) Phase 3
Completed NCT05693051 - Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Completed NCT03764319 - Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO N/A
Recruiting NCT05762029 - Treatment of Extracorporeal Membrane Oxygenation in Severe Poisoning
Completed NCT02995811 - Characterising Changes in Muscle Quantity and Quality in Patients Requiring ECMO Oxygen During Critical Illness
Recruiting NCT04754854 - Reduction of Blood Recirculation in Veno-Venous ECMO